Table 1– Baseline clinical, functional and haemodynamic data of patients with benfluorex-associated pulmonary arterial hypertension (PAH) in comparison with a cohort of patients with fenfluramine and dexfenfluramine-associated PAH
BenfluorexDexfenfluramine and fenfluraminep-value#
Subjects n70109
Age yrs61 (51–71)52 (44–59)<0.0001
Sex M:F ratio1:31:19<0.0001
BMI kg·m−230 (26–34)27 (24–33)<0.05
Delay between first anorexigen exposure and PAH diagnosis months108 (60–144)78 (43–140)ns
Anorexigen exposure duration months30 (12–70)6 (3–12)<0.001
NYHA-FC
 II12 (17)15 (14)
 III52 (74)71 (65)ns
 IV6 (9)23 (21)
6MWD m319 (209–372)250 (121–355)<0.01
Haemodynamics
Pra mmHg9±511±6<0.05
 Mean PAP mmHg47±1160±12<0.0001
Ppcw mmHg10±49±3ns
 CI L·min−1·m−22.4±0.62.2±0.6ns
 PVRI mmHg·L−1·min−1·m−217±826±11<0.0001
  • Data are presented as median (interquartile range), n (%) or mean±sd, unless otherwise stated. M: male; F: female; BMI: body mass index; NYHA-FC: New York Heart Association-functional class; 6MWD: 6-min walk distance; Pra: right atrial pressure; PAP: pulmonary artery pressure; Ppcw: pulmonary capillary wedge pressure; CI: cardiac index; PVRI: pulmonary vascular resistance index; ns: not significant #: comparison between continuous data was performed using an unpaired t-test. A Chi-squared test was used for group data comparison.